Head-to-head evidence
GSK5784283 vs tezepelumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
GSK5784283
Developed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07712393 (registry estimate)
tezepelumab · Tezspire
Marketed by AstraZeneca and partners
NCT03347279 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,061 participants. Both prespecified primary clinical endpoints were met: tezepelumab significantly reduced annual asthma exacerbations overall and in the lower-eosinophil subgroup, with p<0.001 for each comparison.
Next expected readout: November 2026 · NCT06705764 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GSK5784283's landscape · tezepelumab's landscape